Revvity Dihydroalprenolol Hydrochloride, Levo-[Ring, Pr

Revvity 250 µCi quantities of Dihydroalprenolol Hydrochloride, Levo-[Ring, Propyl-³H(N)]-, are available for research. Dihydroalprenolol acts as an antagonist at beta adrenergic receptors. Beta blockers have been used to treat high blood pressure, heart arhythmia, and heart attack. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity We offer both agonist and antagonist radioligands for autoradiographic visualization or performing saturation and competition assays to determine receptor expression levels (B_max), dissociation constants (K_d), association and dissociation rates (k_on and k_off), and inhibitor constants (K_i) for a variety of receptors. We develop our radioligands to the highest specific activity possible and provide high purity resulting in low non-specific binding products. Each of our ultra-pure radioligands is fully characterized for pharmacological action and validated in receptor binding assays. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity Radiolabeled ligands remain the most sensitive method for probing receptor binding biology; yielding unprecedented sensitivity gives results that technicians and scientists can trust. For over 50 years, Revvity has been a leading supplier of New England Nuclear (NEN) radiochemicals, liquid scintillation cocktails, vials and nuclear counting detection instruments. - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Revvity References for NET720: - REVPFZ (Additional S&H Or Hazmat Fees May Apply)

Wolfgang Krawirtz, Erland Erdmann, Specific and unspecific binding of [3H](−)dihydroalprenolol to cardiac tissue, In Biochemical Pharmacology, Volume 28, Issue 8:1283-1288 (1979).Jir S. Tsai and A. Chen. Effect of L-triiodothyronine on (−)3H-dihydroalprenolol binding and cyclic AMP response to (−)adrenaline in cultured heart cells. Nature 275, 138–140 (1978).